OncoMed Halts Early-Stage Trials for Two Cancer Drugs

June 13, 2014 1:12 PM

2 0

OncoMed Pharmaceuticals Inc. on Friday said it halted patient enrollment in two early-stage trials for drugs targeting cancer stem cells.

The company said adverse events related to bones were observed in 13% of patients treated with vantictumab and 5% of patients treated with Fzd8-Fc, both of which are intended to inhibit signaling between cancer stem cells’ pathways.

Read more

To category page